Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCM/EADO 2021 | Neoadjuvant targeted therapy in BRAF V600 mutated melanoma

Piotr Rutkowski, MD, PhD, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, describes a real-world study evaluating the efficacy of neoadjuvant targeted therapy for resectable stage IIIB-D or IV BRAF V600 mutation-positive melanoma. In the study, 29 patients received BRAF/MEK inhibitor treatment at a median time of 16 weeks before surgery. The results demonstrate that 8 patients achieved a complete pathologic response and a significantly improved progression free survival (PFS) was seen in patients with a pathological response of less than 10% viable cells in the tumor. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.

Disclosures

Piotr Rutkowski, MD, PhD has received honoraria for lectures and Advisory Boards from MSD, BMS, Novartis, Pierre Fabre, Sanofi, Merck and Blueprint Medicines.